A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

This outcome measure reports change from baseline in FPG to week 26 measured in terms of milligrams per deciliter (mg/dL).

This outcome measure reports change from baseline to week 26 in BMI measured in terms of the SDS. BMI SDS was calculated based on the WHO 2007 growth reference for children and adolescents. The BMI SDS formula comes from the LMS method as: Z = (\[BMI/M)\]\^L-1)/ L×S where: L=Skewness (Box-Cox power); M=Median; S= (Coefficient of Variation).

This outcome measure reports change from baseline to week 52 in HbA1c measured in terms of percentage point.

This outcome measure reports change from baseline to week 52 in HbA1c measured in terms of mmol/mol.

This outcome measure reports change from baseline to week 52 in FPG measured in terms of mg/dL.

This outcome measure reports change from baseline to week 26 and week 52 in body weight measured in terms of kg.

This outcome measure reports relative change from baseline to week 26 and week 52 in body weight measured in terms of percent change.

This outcome measure reports change from baseline to week 26 and week 52 in Waist circumference measured in terms of centimeters (cm).

This outcome measure reports change from baseline to week 52 in BMI measured in terms of SDS. BMI SDS was calculated based on the WHO 2007 growth reference for children and adolescents. The BMI SDS formula comes from the LMS method: Z = (\[BMI/M)\]\^L-1)/ L×S where: L=Skewness (Box-Cox power), M=Median, S= (Coefficient of Variation)

This outcome measure reports change from baseline (Week 0) in BMI percentile on gender and age-specific growth charts change in terms of percentile of BMI to week 26 and week 52. BMI Percentile was calculated using the CDC 2000 Reference Growth Charts and was derived using the standard LMS method. The CDC reference-specific parameters - L (Lambda), M (Median) and S (Coefficient of Variation) were extracted from the CDC reference tables based on each subject's age (in months) and sex. These parameters were used to compute BMI Z-scores, which were subsequently converted to percentiles using the standard normal distribution function.

This outcome measure reports change from baseline to week 52 in BMI measured in terms of Kilograms per meter square (kg/m\^2).

This outcome measure reports percent change from baseline to week 26 and week 52 in BMI measured in terms of percent change.

This outcome measure reports change from baseline (week 0) in BMI percentage of the 95th percentile in terms of percentage point to week 26 and week 52. BMI Percentage of the 95th Percentile was calculated using the CDC 2000 Reference Growth Charts and was calculated as the ratio of the subject's observed BMI to the CDC age-and-sex-specific 95th percentile BMI reference value, expressed as a percentage.

This outcome measure reports change from baseline in systolic and diastolic blood pressure at week 26 and week 52.

This outcome measure reports percentage of participants with HbA1c \<7.0% at week 26 and week 52 in terms of Yes, No, and Missing.

This outcome measure reports percentage of participants with HbA1c \<6.5% (48 mmol/mol) at week 26 and week 52 in terms of Yes, No, and Missing.

This outcome measure reports number of events with initiation of additional anti-diabetic medication . Anti-diabetic medication was defined as new anti-diabetic medication and/or intensification of anti-diabetic medication initiated at or after randomization and before (planned) end-of-treatment.

This outcome measure reports number of events with initiation of rescue medication. Rescue medication is defined as new anti-diabetic medication and/or intensification of antidiabetic medication initiated at or after randomization and before last date on trial product. This is a subset of the additional anti-diabetic medication.

This outcome measure reports number of TEAEs during exposure to trial product for all participants in each arm were assessed up to approximately 57 weeks. Adverse event (AE) is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain amount of time after the study has ended. TEAE is defined as an AE with onset in the on-treatment observation period.

This outcome measure reports number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes from randomization to week 26. Data reflects the total number of episodes across all participants in each arm. Treatment-emergent hypoglycaemic episodes is defined as treatment-emergent, if the onset of the episode occurs in the on-treatment period. Severe hypoglycaemia according to the International Society for Paediatric and Adolescent Diabetes (ISPAD) classification included response to the following question as yes or no; Question- was the hypoglycaemic episode associated with severe neuroglycopenia, usually resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose)?